Deepankumar Kanagavel

Deepankumar Kanagavel


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in Materials Advances
Verified
Journal Article
Open access
PDF file
SHSAMSON PRINCE H
SAMSON PRINCE H
DKDeepankumar Kanagavel
Deepankumar Kanagavel
Suckerin biomaterials offer elasticity, biocompatibility, and β-sheet self-assembly. Superior to other proteins, they excel in adaptability. Nanotechnology and succinylation boost drug delivery, tissue repair, and wound healing.

3 September 2025 in Neural Regeneration Research
Verified
Journal Article
Open access
APAstha Parikh
Astha Parikh
ACAnas Cholavaram
Anas Cholavaram
ABAjith Kumar Chitti Babu
Ajith Kumar Chitti Babu
DKDeepankumar Kanagavel
Deepankumar Kanagavel
MVMurali Vijayan
Murali Vijayan
Voltage-dependent anion channel 1 is an integral outer membrane protein of the mitochondria that governs apoptosis, enables metabolite exchange, and influences mitochondrial activity. In neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease, oxidative stress, neuroinflammation, and mitochondrial dysfunction are frequent features. Voltage-dependent anion channel 1 is a key regulator of these processes. This review described the structure, membrane topology, and physiological function of voltage-dependent anion channel 1 in neurons and glial cells. We emphasize how it affects mitophagy, oxidative damage, and changes in mitochondrial permeability. Special attention is focused on how voltage-dependent anion channel 1 interacts with pathogenic proteins that damage mitochondrial integrity and cause neurotoxicity, including mutant huntingtin, phosphorylated tau, α-synuclein, amyloid-beta, and TAR DNA-binding protein 43. Furthermore, the paper examines the function of voltage-dependent anion channel 1 in astrocytic dysfunction and microglial activation, highlighting its impact on neuroinflammation. In a nutshell, we assess treatment strategies that target voltage-dependent anion channel 1, such as VBIT-4, a selective inhibitor of voltage-dependent anion channel 1 oligomerization, and newer methods, including structure-based drug design and CRISPR/Cas9 regulation. Improved knowledge of the hinter voltage-dependent anion channel 1 of the molecular mechanism may allow for new therapeutic approaches in neurodegenerative diseases.

1 April 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SMShatakshi Mishra
Shatakshi Mishra
BSB. Stany
B. Stany
ADAnushka Das
Anushka Das
DKDeepankumar Kanagavel
Deepankumar Kanagavel
MVMurali Vijayan
Murali Vijayan

15 March 2025
Verified
Book Chapter
Closed access
PDF file
HPH. Samson Prince
H. Samson Prince
NMNazarene Marylene Nicky Macarius
Nazarene Marylene Nicky Macarius
SWSanket Chandrashekhar Walkikar
Sanket Chandrashekhar Walkikar
SDShubankar Das
Shubankar Das
ARAnand Prem Rajan
Anand Prem Rajan
DKDeepankumar Kanagavel
Deepankumar Kanagavel

25 May 2026 in GeroScience
Verified
Journal Article
Open access
SHSamson Prince Hiruthyaswamy
Samson Prince Hiruthyaswamy
DRDinesh Rao
Dinesh Rao
SBSreeja Balakrishna
Sreeja Balakrishna
NMNazarene Marylene Nicky Macarius
Nazarene Marylene Nicky Macarius
YSYukesh Kumar Sakthivel
Yukesh Kumar Sakthivel
MVMurali Vijayan
Murali Vijayan
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by progressive cognitive decline driven by amyloid-β plaques, tau neurofibrillary tangles, and extensive neuronal loss. Emerging evidence highlights mitochondrial dysfunction, defective mitophagy, and disrupted proteostasis as pivotal events in disease progression. Transglutaminase TG2, a multifunctional calcium-dependent enzyme, has gained attention for its capacity to link these pathological processes. Beyond catalyzing ε-(γ-glutamyl)-lysine crosslinks that stabilize amyloid and tau aggregates, TG2 interacts with mitochondrial membranes, altering permeability and bioenergetic efficiency. In neurons, aberrant TG2 activity promotes oxidative stress, impairs mitophagy through crosslinking of PINK1 and Parkin, and exacerbates calcium dyshomeostasis via modification of VDAC and ANT1, culminating in energy failure and apoptosis. Aging-related increases in ROS and inflammatory cytokines further amplify TG2 activation, reinforcing proteostatic collapse and synaptic degeneration. Recent metabolomic studies reveal that TG2-mediated dysregulation extends to lipid and amino acid metabolism, affecting mitochondrial respiration and neuronal signaling. Therapeutically, selective TG2 inhibition restores autophagic flux, mitigates mitochondrial damage, and reduces aggregate burden in preclinical models. This integrative review underscores TG2 as a central orchestrator connecting mitochondrial dysfunction, aging, mitophagy failure, and metabolic imbalance in AD. Targeting TG2's transamidase activity while preserving its regulatory roles may offer a promising strategy for neuroprotection and disease modification.

21 January 2026 in Small
Verified
Journal Article
Closed access
SLSuyoung Lee
Suyoung Lee
SYSurim Yoo
Surim Yoo
DKDeepankumar Kanagavel
Deepankumar Kanagavel
ASAnastasia Shebanova
Anastasia Shebanova
AMAli Miserez
Ali Miserez
DHDong Soo Hwang
Dong Soo Hwang